The announcement of Carisma Therapeutics presenting new preclinical data at a significant industry event like the ASGCT Annual Meeting is likely to generate positive sentiment among investors and stakeholders. The focus on engineered macrophage cell therapy for liver and lung fibrosis, along with the potential of its Redirected Soluble Modulator technology, highlights the company's innovative approach in the biotech field. This could lead to increased investor interest and potentially positive movement in the stock price in the short term, given the importance of such innovations in driving company value.